From the perspective of clinical translation, targeted small-molecule inhibitors of the PI3K/AKT/mTOR cascade merit particular attention, as they afford highly selective modulation of RA-FLS activity while minimizing off-target effects and expanding the therapeutic window. The gene discussed is MTOR; the disease is rheumatoid arthritis.